Role of C5A in inflammatory responses

被引:767
作者
Guo, RF [1 ]
Ward, PA [1 ]
机构
[1] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
关键词
complement; C5a receptor; C5L2; inflammation;
D O I
10.1146/annurev.immunol.23.021704.115835
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The complement system not only represents an effective innate immune mechanism of host defense to eradicate microbial pathogens, but it is also widely involved in many forms of acute and chronic inflammatory diseases including sepsis, acute lung injury, ischemia-reperfusion injury, and asthma, to give just a few examples. The complement-activated product, C5a, displays powerful biological activities that lead to inflammatory sequelae. C5a is a strong chemoattractant and is involved in the recruitment of inflammatory cells such as neutrophils, eosinophils, monocytes, and T lymphocytes, in activation of phagocytic cells and release of granule-based enzymes and generation of oxidants, all of which may contribute to innate immune functions or tissue damage. Accumulating data suggest that C5a provides a vital bridge between innate and adaptive immune functions, extending the roles of C5a in inflammation. Herein, we review human and animal data describing the cellular and molecular mechanisms of C5a in the development of inflammatory disorders, sepsis, acute lung injury, ischemia-reperfusion injury, and asthma.
引用
收藏
页码:821 / 852
页数:32
相关论文
共 156 条
  • [81] Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma
    Krug, N
    Tschernig, T
    Erpenbeck, VJ
    Hohlfeld, JM
    Köhl, J
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (10) : 1841 - 1843
  • [82] INTERLEUKIN-3-DEPENDENT MEDIATOR RELEASE IN BASOPHILS TRIGGERED BY C5A
    KURIMOTO, Y
    DEWECK, AL
    DAHINDEN, CA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (02) : 467 - 479
  • [83] Moderation of skeletal muscle reperfusion injury by a sLex-glycosylated complement inhibitory protein
    Kyriakides, C
    Wang, Y
    Austen, WG
    Favuzza, J
    Kobzik, L
    Moore, FD
    Hechtman, HB
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2001, 281 (01): : C224 - C230
  • [84] Expression and function of C5a receptor in mouse microvascular endothelial cells
    Laudes, IJ
    Chu, JC
    Huber-Lang, M
    Guo, RF
    Riedemann, NC
    Sarma, JV
    Mahdi, F
    Murphy, HS
    Speyer, C
    Lu, KT
    Lambris, JD
    Zetoune, FS
    Ward, PA
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 169 (10) : 5962 - 5970
  • [85] Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis
    Laudes, IJ
    Chu, JC
    Sikranth, S
    Huber-Lang, M
    Guo, RF
    Riedemann, N
    Sarma, JV
    Schmaier, AH
    Ward, PA
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (05) : 1867 - 1875
  • [86] Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome
    Le Tulzo, Y
    Pangault, C
    Gacouin, A
    Guilloux, V
    Tribut, O
    Amiot, L
    Tattevin, P
    Thomas, R
    Fauchet, R
    Drénou, B
    [J]. SHOCK, 2002, 18 (06): : 487 - 494
  • [87] Complement inhibition by soluble complement receptor type 1 improves microcirculation after rat liver transplantation
    Lehmann, TG
    Koeppel, TA
    Kirschfink, M
    Gebhard, MM
    Herfarth, C
    Otto, G
    Post, S
    [J]. TRANSPLANTATION, 1998, 66 (06) : 717 - 722
  • [88] Impact of inhibition of complement by sCR1 on hepatic microcirculation after warm ischemia
    Lehmann, TG
    Koeppel, TA
    Münch, S
    Heger, M
    Kirschfink, M
    Klar, E
    Post, S
    [J]. MICROVASCULAR RESEARCH, 2001, 62 (03) : 284 - 292
  • [89] Complement activation and inhibition in experimental models of arthritis
    Linton, SM
    Morgan, BP
    [J]. MOLECULAR IMMUNOLOGY, 1999, 36 (13-14) : 905 - 914
  • [90] Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction - The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
    Mahaffey, KW
    Granger, CB
    Nicolau, JC
    Ruzyllo, W
    Weaver, WD
    Theroux, P
    Hochman, JS
    Filloon, TG
    Mojcik, CF
    Todaro, TG
    Armstrong, PW
    [J]. CIRCULATION, 2003, 108 (10) : 1176 - 1183